Clinical trials: Orbitopathy, Graves
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-1 (NCT07720635)
- Testing
- KHN939
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Graves Ophthalmopathy
Glucocorticoids and Bone in Graves' Ophthalmopathy
Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid.
- Trial name
- NCT03122847
- Testing
- Methylprednisolone
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Torben Harsløf
Graves Disease, Graves Ophthalmopathy
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
Introduction: Graves disease (GD) is characterized by thyrotoxicosis and goiter, arising through circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR).
- Conditions
- Graves Disease, Graves Ophthalmopathy, Graves' Ophthalmopathy Worsened
- Trial name
- NCT03066076
- Testing
- Antithyroid Drug, Total thyroidectomy
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Graves Ophthalmopathy, Graves Disease
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
The study is aimed at assessing IGF-1R-Abs in patients with Graves' disease, with or without GO, compared with healthy subjects and patients with autoimmune thyroiditis in a cross-sectional investigation.
- Conditions
- Graves Ophthalmopathy, Graves Disease, Autoimmune Thyroiditis
- Trial name
- IGF1RAbsGO (NCT03498417)
- Testing
- Serum antibodies against the IGF-1R
- Where
- Italy
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Thyroid Associated Ophthalmopathies
MHB018A Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants…
- Trial name
- NCT06989918
- Testing
- MHB018A
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.
- Trial name
- NCT00424151
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Silkiss, Rona Z., M.D., FACS
Thyroid Eye Disease
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease.
- Trial name
- NCT05795621
- Testing
- IBI311
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Patients with Thyroid Eye Disease (TED) often have enlarged extraocular muscles and higher orbital fat contents due to their disease process.
- Trial name
- NCT01798966
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sensimed AG
Thyroid Associated Ophthalmopathy
Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy
The purpose of this study is to determine whether combination of orbital compression surgery with strabismus surgery is better than strabismus surgery after orbital compression surgery in the treatment of moderate-to-severe…
- Trial name
- NCT04919694
- Testing
- combination of orbital compression surgery and strabismus surgery, orbital compression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Graves' Ophthalmopathy (GO)
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants.
- Trial name
- NCT03938545
- Testing
- RVT-1401 (Administered via subcutaneous injection)
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Eye Disease, Graves' Orbitopathy
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R]) administered once every 3…
- Trial name
- OPTIC (NCT03298867)
- Testing
- Teprotumumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Amgen
Dysthyroid Ophthalmopathies
mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)
The dysthyroid orbitopathy (DO) is a chronic disease, evolving during 2 to 3 years, with a hypertrophy and a variable degree of inflammation of the eyelid muscles, the oculomotor muscles and the orbital fat.
- Trial name
- DDX (NCT02397109)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Graves' Orbitopathy
A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study
Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD). Based on its clinical signs and symptoms, GO is graded as mild, moderate-to-severe, or severe, and active or inactive, the latter…
- Trial name
- STAGO-2 (NCT05049603)
- Testing
- Atorvastatin 20mg
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy
Graves' orbitopathy (GO) is an disfiguring and disabling autoimmune condition. Sight-threatening GO is an most severe form and occurs in about 5% of patients with Graves' disease.
- Trial name
- NCT05627401
- Testing
- Modified multiple orbital wall decompression
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Graves Ophthalmopathy
Thyroid Treatment Trial
This project will compare the efficacy and safety of 2 methods of disease modification in the treatment of active moderate and severe thyroid orbitopathy.
- Trial name
- NCT00348413
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- Singapore National Eye Centre
Thyroid-Associated Ophthalmopathy
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
The purpose of this study is to determine whether injection of autologous fat or hyaluronic-acid injections in temporal region are effective in the treatment of temporal hollowing after lateral wall decompression in patients with…
- Trial name
- NCT02693808
- Testing
- Autologous fat injection, Hyaluronic acid injection
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Haukeland University Hospital
Thyroid Disease
Local Triamcinolone Injection in Active Thyroid Orbitopathy
Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.
- Trial name
- NCT01280214
- Testing
- Triamcinolone
- Volunteers
- 30 people
- Sponsor
- HaEmek Medical Center, Israel
Graves Ophthalmopathy
Bimatoprost as a Treatment for Graves' Orbitopathy
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
- Trial name
- NCT03708627
- Testing
- Bimatoprost Ophthalmic
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University